Caliway’s CBL-514 cuts Dercum’s disease pain in Phase 2 trial
AI Summary- Caliway Biopharmaceuticals reported that CBL-514 met the Phase 2 Dercum’s Disease primary endpoint.
- CBL-514 reduced Week 20 pain scores by 3.1 points versus 1.9 points for placebo in the FAS population.
- Caliway plans to evaluate CBL-514’s development potential for Lipedema with clinical experts.